NCT00715182已完成1 期
A Phase I/II Multi-center, Open Label Study of TKI258 Administered Orally on an Intermittent Schedule in Adult Patients With Advanced or Metastatic Renal Cell Cancer (RCC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 87
- 试验地点
- 1
- 主要终点
- Phase I: To determine the MTD of TKI258, administered orally on a 5 days on/2 days off schedule to adult patients with advanced or metastatic RCC whose diseases have progressed despite standard therapy or for whom no standard anticancer therapy exists.
研究概览
简要总结
This is a phase I/II open-label study to delineate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of TKI258. The eligible subject population consists of subjects who have been diagnosed with advanced or metastatic renal cell cancer that is refractory to standard therapy or for which no curative standard therapy exists.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For phase I, confirmed advanced/ metastatic renal cell carcinoma for which no other therapeutic options exist.
- •For phase II, must have been previously treated with VEGF receptor tyrosine kinase inhibitor (sunitinib and/or sorafenib).
- •For phase II, must have at least one measurable lesion at baseline.
- •For both phase I & II, measurable histologically or cytology confirmed progressive metastatic renal cell carcinoma with predominant clear cell histology (>50%).
- •At least 4 weeks must have elapsed since any prior anti-cancer therapy (6 weeks for nitrosoureas or mitomycin C).
- •Must have recovered from adverse events (to grade 1 or less toxicity according to CTCAE 3.0) due to agents administered more than 28 days earlier.
- •Must be eighteen years of age or older
- •ECOG performance status 0 or
- •Must meet baseline laboratory requirement
- •Life expectancy greater than or equal to 12 weeks.
- •Signed and witnessed informed consent prior to any screening procedures.
排除标准
- •Concurrent therapy with any other investigational agent within 28 days prior to baseline.
- •Pregnant or breast feeding women.
- •Clinically significant cardiac disease (New York Heart Association, Class III or IV) or impaired cardiac function or clinically significant cardiac diseases.
- •Uncontrolled infection.
- •Diabetes mellitus with signs of clinically significant peripheral vascular disease.
- •Previous pericarditis; clinically significant pleural effusion in the previous 12 months or current ascites requiring two or more interventions/month.
- •Known pre-existing clinically significant disorder of the hypothalamic-pituitary axis, adrenal or thyroid glands.
- •Prior acute or chronic pancreatitis of any etiology.
- •Acute and chronic liver disease and all chronic liver impairment.
- •Malabsorption syndrome or uncontrolled gastrointestinal symptoms (such as nausea, diarrhea and vomiting) with toxicity greater than NCI CTCAE grade
- •Other severe, acutem or chronic medical or psychiatric condition or laboratory abnormality that may interfere with the interpretation of study results and, in the judgement of the investigator, would make the subject inappropriate for this study.
- •Treatment with any of the medications that have a potential risk of prolonging the QT interval or inducing Torsades de Points and the treatment cannot be discontinued or switched to a different medication prior to starting study drug.
- •Use of ketoconazole, erythromycin, carbamazapine, phenobarbital, rifampin, phenytoin and quinidine 2 weeks prior to baseline.
- •Major surgery within 28 days prior to starting study drug or who have not recovered from side effects of such therapy.
- •Known diagnosis of HIV infection (HIV testing is not mandatory).
- •History of another clinically significant primary malignancy that requires active intervention.
- •Patients with brain metastases as assessed by radiologic imaging.
- •Alcohol or substance abuse disorder.
研究组 & 干预措施
TKI258
Experimental
干预措施: TKI258 (Drug)
结局指标
主要结局
Phase I: To determine the MTD of TKI258, administered orally on a 5 days on/2 days off schedule to adult patients with advanced or metastatic RCC whose diseases have progressed despite standard therapy or for whom no standard anticancer therapy exists.
时间窗: at end of phase I
Phase II: To determine anti-tumor activity of TKI258 in advanced or metastatic RCC patients with predominant clear cell histology that have been previously treated with VEGF receptor tyrosine kinase inhibitor (sunitinib and/or sorafenib).
时间窗: at end of phase II
次要结局
- To characterize the single and multiple-dose PK profiles of oral TKI258(cycle 1: day 1, 8, 15 &26; cycle 2 & 3: day 15 & 28)
- To assess the safety profile of TKI258(cycle 1: day 1,8,15,26; cycle 2: day 15, 28; cycle 3+: day 28 & at end of study)
- To explore the pharmacokinetic and pharmacodynamic relationship(end of study)
- To assess the effect of TKI258 on plasma biomarkers, pre- and post-treatment(cycle 1: day 1,15,26; cycle 2: 15 & 28; every other cycles: day 28 & at end of study)
- Progression free survival and over all survival(end of study)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid TumorsAdvanced High-grade Ovarian CancerTriple Negative Breast CancerNCT03333915BeiGene128
已完成
1 期
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsAdvanced Solid TumorHER2-negative Breast CancerTriple Negative Breast CancerSmall-cell Lung CancerGallbladder CancerGastric CancerBladder CancerSarcomaProstate CancerCholangiocarcinomaThyroid CancerNCT04742959TransThera Sciences (Nanjing), Inc.203
已完成
1 期
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)Advanced Solid TumorsNCT03179436Merck Sharp & Dohme LLC415
已完成
1 期
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With GlioblastomaGlioblastomaNCT05187624Hoffmann-La Roche36
招募中
1 期
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid TumorsAdvanced Solid TumorCervical CancerNCT06223308Shanghai Huaota Biopharmaceutical Co., Ltd.54